Prosecution Insights
Last updated: April 19, 2026

Moonlake Immunotherapeutics AG

4 pending office actions

Portfolio Summary

4
Total Pending OAs
3
Final Rejections
1
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
19187625 BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS HADDAD, MAHER M 1641 Final Rejection Apr 23, 2025
19187629 BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS FRITCHMAN, REBECCA M 1758 Final Rejection Apr 23, 2025
19187615 BIOMARKER-BASED TREATMENT AND DIAGNOSTIC METHODS FOR IL-17-DEPENDENT CONDITIONS JIANG, DONG 1674 Final Rejection Apr 23, 2025
18921679 METHODS OF ACHIEVING SAFE AND SUSTAINED CONTROL OF IL-17-DEPENDENT CONDITIONS IN SUBJECTS RESPONSIVE TO TREATMENT WITH AN ANTI-IL 17A/F NANOBODY JIANG, DONG 1674 Non-Final OA Oct 21, 2024

Managing Moonlake Immunotherapeutics AG's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month